Provigil FAERS Safety Signals: What FDA Post-Market Data Show About Modafinil

What FAERS Is and Why It Matters for Modafinil

The FDA Adverse Event Reporting System (FAERS) is a voluntary, passive surveillance database that captures adverse drug events reported by clinicians, patients, and manufacturers after a drug reaches the market. Pre-approval clinical trials for modafinil enrolled relatively modest populations. The key US Modafinil in Narcolepsy Multicenter Study (N=283) established efficacy and captured short-term tolerability but could not detect events occurring at rates below roughly 1 in 100 1.

FAERS fills that gap. Since Provigil's approval on December 24, 1998, the database has accumulated thousands of modafinil-related case reports. These reports drove multiple label revisions, including the addition of warnings for serious dermatologic reactions, psychiatric symptoms, and cardiac events 2. Passive surveillance cannot prove causation. It can, and routinely does, generate signals strong enough to change prescribing practice.

A 2007 FDA review of FAERS data for modafinil identified a disproportionality signal for serious skin reactions that exceeded the reporting threshold for regulatory action. The agency issued a public health advisory and required Cephalon to add specific dermatologic warnings to the Provigil label 3. That sequence (signal detection, advisory, label change) represents the standard FAERS-to-action pipeline.

Serious Dermatologic Reactions: The SJS/TEN Signal

Serious skin reactions represent the most clinically consequential FAERS signal for modafinil. The current Provigil label warns that cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in adults and children during post-marketing surveillance, with some cases requiring hospitalization.

The FDA's 2007 Pediatric Advisory Committee review examined modafinil FAERS data alongside a pediatric ADHD trial program. Among approximately 933 pediatric patients exposed to modafinil in clinical trials, one confirmed case of erythema multiforme and several probable cases of SJS were identified 3. This rate exceeded background incidence for SJS in the general pediatric population, which the FDA estimated at 1 to 6 per million person-years 4. Cephalon's supplemental NDA for pediatric ADHD was ultimately not approved, partly on the basis of this dermatologic safety signal.

In the adult FAERS dataset, SJS/TEN reports remain rare but consistently present. The label now instructs clinicians to discontinue modafinil at the first sign of rash unless the rash is clearly not drug-related. No pharmacogenomic biomarker (such as HLA-B*1502, which predicts carbamazepine-associated SJS in certain populations) has been validated for modafinil-associated skin reactions. That means clinical vigilance remains the primary mitigation strategy.

Time to onset matters. Most reported cases developed within the first five weeks of therapy. The label recommends that patients and prescribers maintain heightened awareness during this early treatment window.

Psychiatric Adverse Events in FAERS

FAERS contains a substantial volume of psychiatric adverse event reports for modafinil, spanning anxiety, insomnia, agitation, psychosis, mania, hallucinations, and suicidal ideation. The Provigil prescribing label addresses these under the "Psychiatric Symptoms" subsection of Warnings and Precautions 2.

Pre-approval trials detected psychiatric signals at modest rates. In the key narcolepsy study, anxiety occurred in 5% of modafinil-treated patients versus 1% on placebo, and insomnia occurred in 5% versus 1% 1. Post-market reporting expanded this picture considerably. FAERS cases include psychotic episodes in patients with no prior psychiatric history, manic episodes in patients with previously stable bipolar disorder, and suicidal ideation emerging shortly after modafinil initiation.

A 2019 pharmacovigilance analysis of the FAERS database using disproportionality methods found that modafinil carried a statistically significant reporting odds ratio for hallucinations and suicidal ideation compared to all other drugs in the database 5. Disproportionality does not equal causation. Patients prescribed modafinil often carry comorbid psychiatric diagnoses, and confounding by indication is a recognized limitation of FAERS-based signal detection.

The clinical takeaway: screen patients for a personal or family history of psychosis, depression, or mania before initiating modafinil. The FDA label specifically advises considering dose reduction or discontinuation if psychiatric symptoms emerge.

Cardiovascular Signals: Chest Pain, Palpitations, and Beyond

Cardiovascular adverse events in the modafinil FAERS dataset cluster around chest pain, palpitations, tachycardia, and hypertension. Rare cases of ischemic events have also been reported 2.

Modafinil's mechanism of action involves inhibition of dopamine reuptake and downstream sympathomimetic effects. Heart rate increases of 1 to 3 beats per minute and systolic blood pressure increases of 1 to 3 mmHg were observed in controlled trials, effects that were statistically detectable but clinically modest in healthy adults 6. The concern shifts when modafinil is used in patients with pre-existing cardiovascular disease, mitral valve prolapse, or left ventricular hypertrophy.

The Provigil label recommends that modafinil not be used in patients with a history of left ventricular hypertrophy or cor pulmonale. Patients with recent myocardial infarction or unstable angina were excluded from clinical trials, and no safety data exist for these populations. The label states that blood pressure monitoring is advised in treated patients.

FAERS reports of modafinil-associated chest pain are difficult to interpret in isolation because the drug is frequently prescribed to shift workers and patients with obstructive sleep apnea, populations that carry elevated baseline cardiovascular risk. Signal-to-noise separation requires formal epidemiologic study designs that go beyond spontaneous reporting.

Abuse Potential and Dependence: What FAERS and Scheduling Data Show

Modafinil is classified as a Schedule IV controlled substance under the Controlled Substances Act, placing it in the same regulatory category as benzodiazepines and zolpidem. The scheduling decision was based on pre-approval abuse liability studies showing that modafinil produces psychoactive and euphoric effects at supratherapeutic doses, though its reinforcing properties are weaker than those of amphetamines 7.

FAERS contains reports of drug dependence, withdrawal, and intentional misuse associated with modafinil. The European Medicines Agency (EMA) conducted a separate review in 2010 and concluded that the benefit-risk balance for modafinil was favorable only for narcolepsy, recommending against its use for idiopathic hypersomnia and obstructive sleep apnea on the basis of cardiovascular and skin safety signals combined with limited efficacy in those populations 8.

In the US, the FDA has not restricted modafinil's indications. The divergence between US and European regulatory responses to overlapping FAERS and EudraVigilance data illustrates how different agencies weigh the same safety signals against different benefit thresholds.

Clinicians should assess patients for substance use history before prescribing. The label notes that modafinil tablets should be stored securely and that prescription quantities should be minimized to reduce diversion risk.

Drug Interactions Flagged Through Post-Market Reporting

FAERS case reports and pharmacokinetic studies have identified clinically relevant drug interactions that were not fully characterized in the original approval package. Modafinil is a moderate inducer of CYP3A4 and an inhibitor of CYP2C19 2.

The CYP3A4 induction effect reduces plasma concentrations of hormonal contraceptives. This interaction carries direct clinical consequences: women relying solely on oral, patch, or ring contraceptives may experience contraceptive failure during modafinil therapy and for one month after discontinuation. The label recommends alternative or additional contraceptive methods. FAERS contains reports of unintended pregnancy in women taking modafinil alongside hormonal contraceptives.

The CYP2C19 inhibition can raise levels of drugs metabolized by that pathway, including omeprazole, phenytoin, and diazepam. Dose adjustments may be necessary when modafinil is co-administered with CYP2C19 substrates that have narrow therapeutic indices.

Cyclosporine exposure may decrease by up to 50% when taken with modafinil. One published case report documented a transplant patient whose cyclosporine trough levels dropped below the therapeutic range after modafinil initiation, requiring a dose increase 9. This interaction was added to the Provigil label as a post-market update.

How FAERS Signal Detection Works for Modafinil

The FDA uses two primary disproportionality methods to mine FAERS data: the Multi-item Gamma Poisson Shrinker (MGPS) and the Empirical Bayesian Geometric Mean (EBGM). Both compare the observed reporting frequency of a specific drug-event pair against the expected frequency based on all other drugs and events in the database 10.

For modafinil, EBGM scores exceeding the signal threshold (typically an EBGM05 value greater than 2) have been reported for SJS/TEN, angioedema, drug dependence, hallucinations, and suicidal behavior. These scores do not confirm causation. They flag combinations that warrant further investigation through controlled epidemiologic studies, label revision, or both.

The FDA Sentinel System, a distributed data network covering over 100 million patients through electronic health record and claims data, provides a second layer of active surveillance. Sentinel can test specific hypotheses generated by FAERS signals using longitudinal patient-level data. To date, no published Sentinel analysis focused specifically on modafinil has appeared in the public access database, though the infrastructure exists for the agency to run such a query if signal strength warrants it.

Prescribers can query FAERS data directly through the FDA's openFDA platform or the FAERS Public Dashboard. Quarterly data updates lag by approximately three months from the reporting period.

Comparing the Modafinil Safety Profile to Armodafinil

Armodafinil (Nuvigil), the R-enantiomer of modafinil, was approved in 2007 and shares a nearly identical safety profile in FAERS. The same dermatologic, psychiatric, and cardiovascular warnings appear on both labels. FAERS disproportionality scores for SJS/TEN, psychiatric events, and cardiac events are comparable between the two drugs 2.

This is expected. Modafinil is a racemic mixture of R- and S-enantiomers. Armodafinil eliminates the S-enantiomer but retains the pharmacologically active R-form. The half-life of armodafinil is longer (10 to 15 hours versus 12 to 15 hours for R-modafinil after racemic dosing), which may affect the temporal pattern of adverse events but does not meaningfully change the adverse event spectrum.

Clinicians sometimes switch patients from modafinil to armodafinil expecting a different side-effect profile. FAERS data do not support that expectation. The same monitoring recommendations (skin surveillance during the first five weeks, psychiatric screening, blood pressure checks) apply to both drugs.

Practical Monitoring Recommendations Based on FAERS Data

For clinicians prescribing modafinil, the accumulated FAERS evidence translates into a focused monitoring protocol. Check blood pressure at baseline and periodically during treatment. Screen for personal and family psychiatric history before initiation. Counsel patients to report any rash, mouth sores, or skin blistering immediately, especially during the first 35 days of therapy. Review the medication list for CYP3A4 substrates (particularly hormonal contraceptives and cyclosporine) and CYP2C19 substrates with narrow therapeutic windows. Document the rationale for continued use at each refill, especially in patients with cardiovascular risk factors.

The recommended starting dose for narcolepsy and obstructive sleep apnea is 200 mg once daily in the morning 2. Doses up to 400 mg/day have been studied, but controlled trials showed no consistent additional benefit for the higher dose, while adverse event rates increased.